By admin 
The crux of the controversy lies in Capricor’s recent announcement that it intends to use data from an open-label extension (OLE) of its Phase 3 HOPE-3 trial as a primary pillar for its Biologics License Application (BLA). To seasoned biotech observers and regulatory hawks, this move looks less like a strategic pivot and more like a desperate "Hail Mary" pass in the final seconds of a losing game. In the world of drug development, particularly within the scrutinized halls of the FDA’s Office of Therapeutic Products, open-label data is rarely considered a substitute for a randomized, double-blind, placebo-controlled trial—the gold standard of clinical evidence.
Duchenne muscular dystrophy is a devastating, X-linked genetic disorder characterized by the progressive loss of muscle function, eventually leading to respiratory failure and cardiomyopathy. While much of the recent industry focus has been on gene therapies like Sarepta Therapeutics’ Elevidys, which aims to replace the missing dystrophin protein, Capricor’s deramiocel takes a different approach. Deramiocel consists of allogeneic cardiosphere-derived cells (CDCs) that release exosomes containing microRNAs and proteins designed to modulate the immune system, reduce inflammation, and stimulate tissue regeneration. Specifically, Capricor has positioned deramiocel as a therapy for non-ambulatory patients—older boys and young men who have already lost the ability to walk and for whom few treatment options exist.
The company’s confidence appears to stem from the HOPE-2 trial, a smaller Phase 2 study that showed a statistically significant benefit in the Performance of the Upper Limb (PUL) scale, a key metric for assessing function in patients who are wheelchair-bound. However, the subsequent Phase 3 HOPE-3 trial, which was supposed to confirm these findings in a larger population, failed to meet the same level of definitive success under the rigorous conditions of a controlled study. When a Phase 3 trial fails to hit its primary endpoint, the standard operating procedure for a biotech company is to either go back to the drawing board to design a new trial or abandon the program entirely. Capricor has chosen a third, more controversial path: arguing that the long-term data from the patients who continued taking the drug after the trial ended (the OLE) shows a "disease-modifying" effect that the FDA should not ignore.
This strategy is fraught with scientific and regulatory peril. Open-label extensions are notoriously prone to bias. Because both the patients and the investigators know that the active drug is being administered, the results can be skewed by the placebo effect or by the fact that only the healthiest or most responsive patients tend to remain in long-term extensions. Furthermore, without a concurrent placebo group to compare against, it is nearly impossible to prove that any observed stability in the patients’ condition is due to the drug rather than the natural variability of the disease.
Despite these hurdles, Capricor CEO Linda Marbán has remained steadfast in her public communications. In recent earnings calls and investor presentations, the company has emphasized its "constructive" dialogue with the FDA and its plan to submit a rolling BLA. The company’s partnership with the Japanese pharmaceutical firm Nippon Shinyaku, which includes significant milestone payments and a distribution agreement, further complicates the narrative. To maintain the value of this partnership and the confidence of its shareholders, Capricor must project an image of a company on the verge of a regulatory breakthrough.
However, the history of DMD drug approvals suggests that the FDA is a difficult agency to sway with sub-par data. While the agency has shown some flexibility in the past—most notably with the controversial 2016 approval of Sarepta’s Exondys 51—that flexibility was born out of intense pressure from patient advocacy groups and a unique set of circumstances that may not apply to Capricor. In the years since, the FDA has tightened its requirements, demanding more robust evidence of clinical benefit. The recent struggles of other DMD players, such as FibroGen, whose drug pamrevlumab failed in Phase 3, serve as a cautionary tale.
The "stall tactic" mentioned by critics refers to the idea that by filing a BLA based on OLE data, Capricor buys itself more time. A BLA filing starts a clock; it allows the company to remain relevant in the eyes of investors for several more months while the FDA reviews the package. If the FDA eventually issues a Complete Response Letter (CRL)—a formal rejection—Capricor can then argue that they did everything possible for the patient community. But for the families of those with DMD, this delay is more than just a corporate maneuver; it represents a period of false hope.
The financial stakes are also immense. Capricor’s stock price is heavily tethered to the perceived success of deramiocel. Any admission that the current data is insufficient would likely lead to a significant devaluation of the company. This creates a feedback loop where the company must double down on its optimistic outlook to keep the lights on and the research moving forward. Yet, the disconnect between the company’s rhetoric and the statistical reality of the HOPE-3 failure is becoming harder to ignore.
Market analysts have pointed out that even if the FDA were to grant an advisory committee meeting—a public forum where experts debate the drug’s merits—the scrutiny of the OLE data would be intense. Committee members often look unfavorably upon companies that attempt to "cherry-pick" data from failed trials to find a post-hoc success story. The PUL 2.0 metric, while important, is subject to inter-rater variability, and without the shielding of a double-blind study design, its reliability as a primary endpoint in an OLE setting is questionable.
Furthermore, the competitive landscape for DMD is shifting rapidly. With the full approval of Elevidys and the ongoing development of next-generation exon-skipping therapies and other cell-based approaches, the "unmet need" argument that Capricor relies on is slowly losing its potency. While it is true that non-ambulatory patients are underserved, the FDA is unlikely to approve a drug that cannot clearly demonstrate it works better than the current standard of care, which includes corticosteroids and, increasingly, gene therapy.
There is also the question of the cardiac data. Capricor has long touted deramiocel’s potential to improve heart function, measured by Cardiac Magnetic Resonance (CMR) imaging. While the cardiac data from HOPE-2 was intriguing, the FDA typically views imaging biomarkers as "surrogate endpoints" rather than "clinical endpoints." To win approval based on heart health, Capricor would likely need to show that deramiocel prevents heart failure or extends life—outcomes that require years of study and hundreds of patients, far beyond what the current OLE can provide.
The logical conclusion for many in the biotech industry is that Capricor needs a new, well-powered, randomized trial to prove its case. Such a trial would take years and cost tens of millions of dollars—resources the company may not have without significant new investment or a massive leap of faith from its partners. By choosing to push forward with the current data, Capricor is betting that the FDA’s desire to help DMD patients will override its commitment to rigorous statistical standards.
It is a high-stakes gamble with the lives of patients and the capital of investors. While the company’s public confidence remains unshaken, the underlying clinical foundation appears brittle. The FDA’s upcoming decision on whether to even accept the BLA for filing will be the first major test of Capricor’s strategy. If the agency refuses to file, or if it accepts the filing only to issue a scathing review later, the "stall tactic" will be exposed. For now, the biotech world watches and waits, wondering if Capricor knows something the rest of the market doesn’t, or if they are simply whistling past the graveyard of failed clinical trials. In the end, science and data usually have the final word, regardless of how much confidence a company projects to the public.
